https://www.selleckchem.com/products/jhu-083.html
3±1.2 times/year to 0.2±0.3 times/year (P 0.001). The results from the Cox proportional-hazards model showed that the risk of relapse in patients who received RTX non-consolidation treatment was significantly higher than those with consolidation treatment (odds ratios (OR) 20.9, 95% confidence intervals (CI) OR 5.7-75.7, p0.001). The 24-month relapse-free rate was also significantly higher in patients with consolidation therapy compared with non-consolidation therapy (86.36% vs 25%, p0.001). No adverse events were recorded.
Like
Comment
Share
